In fact, genetic reduction of PD‐L1 (+) EXO amounts in Rab27a− or nsMase‐knockout tumor cells suppressed tumor growth in an immune‐dependent fashion.[9a] To overcome this limitation of ICT induced by cancer EXOs, it is necessary to design strategies to control EXO secretion in cancers. This evidence concerns the gene SMPD2 and cancer.